SHAREHOLDER ALERT: Travere Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Should Contact The Firm

Impact · against what's priced in

Travere Therapeutics faces a severe valuation hit due to a regulatory delay and requests for more clinical benefit data for FILSPARI, compounded by a securities fraud investigation. CDNL and CVRX also face new legal headwinds as they are similarly targeted by the same law firm for potential securities fraud.

TVTX−0.90

No priced-in read yet